CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD
作者： DAVID MICHELSON , HOLLY A. READ , DUSTIN D. RUFF , JENNIFER WITCHER , SHUYU ZHANG
DOI: 10.1097/01.CHI.0000246056.83791.B6
关键词:
摘要: ABSTRACT Background Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the treatment of attention-deficit/hyperactivity disorder (ADHD), is metabolized through cytochrome P-450 2D6 (CYP2D6) enzyme pathway, which genetically polymorphic humans. Variations plasma atomoxetine exposures can occur because genetic variation or as consequence coadministration with drugs that inhibit CYP2D6. Method We examined effects CYP2D6 on efficacy, safety, and tolerability children adolescents using pooled data from clinical trials. Results At endpoint, poor metabolizers had markedly greater reductions mean symptom severity scores compared extensive ( p Conclusions These results suggest taking doses up to 1.8 mg/kg/day are likely have increases cardiovascular tone, some differences similar doses.
sci-hub.se 参考文章(21)
C R Wolf, G Smith, Cytochrome P450 CYP2D6. IARC scientific publications. pp. 209- ,(1999)
C Sachse, S Bauer, J Brockmöller, I Roots, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics. ,vol. 60, pp. 284- 295 ,(1997)
Jennifer W. Witcher, Amanda Long, Brian Smith, John-Michael Sauer, John Heilgenstein, Timothy Wilens, Thomas Spencer, Joseph Biederman, Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder Journal of Child and Adolescent Psychopharmacology. ,vol. 13, pp. 53- 63 ,(2003) , 10.1089/104454603321666199
T. J. Spencer, Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics. ,vol. 116, pp. 80- ,(2005) , 10.1542/PEDS.2004-0624
F. Peter Guengerich, Human cytochrome P-450 enzymes. Life Sciences. ,vol. 50, pp. 1471- 1478 ,(1992) , 10.1016/0024-3205(92)90136-D
Thomas Spencer, John H. Heiligenstein, Joseph Biederman, Douglas E. Faries, Christopher J. Kratochvil, C. Keith Conners, William Z. Potter, Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder The Journal of Clinical Psychiatry. ,vol. 63, pp. 1140- 1147 ,(2002) , 10.4088/JCP.V63N1209
Julian B.S. Leathart, Stephanie J. London, Annette Steward, James D. Adams, Jeffrey R. Idle, Ann K. Daly, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. ,vol. 8, pp. 529- 542 ,(1998) , 10.1097/00008571-199812000-00010
LI YANG, YU-FENG WANG, JUN LI, STEPHEN V. FARAONE, Association of norepinephrine transporter gene with methylphenidate response. Journal of the American Academy of Child and Adolescent Psychiatry. ,vol. 43, pp. 1154- 1158 ,(2004) , 10.1097/01.CHI.0000131134.63368.46
Jan K. Buitelaar, David Michelson, Marina Danckaerts, Christopher Gillberg, Thomas J. Spencer, Alessandro Zuddas, Douglas E. Faries, Shuyu Zhang, Joseph Biederman, A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biological Psychiatry. ,vol. 61, pp. 694- 699 ,(2007) , 10.1016/J.BIOPSYCH.2006.03.066
T TATEISHI, M CHIDA, N ARIYOSHI, Y MIZOROGI, T KAMATAKI, S KOBAYASHI, Analysis of the CYP2D6 gene in relation to dextromethorphan O‐demethylation capacity in a Japanese population Clinical Pharmacology & Therapeutics. ,vol. 65, pp. 570- 575 ,(1999) , 10.1016/S0009-9236(99)70077-9